← Back to Search

Other

LY3305677 for Obesity

Phase 2
Recruiting
Research Sponsored by Eli Lilly and Company
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 56
Awards & highlights

Study Summary

This trial will test how effective and safe a new weight-loss medicine (LY3305677) is compared to a placebo in adults with obesity or overweight. It will last 62 weeks.

Who is the study for?
This trial is for adults with obesity or overweight, having a BMI of at least 27 kg/m² and one weight-related health issue. Participants must have maintained stable body weight (less than 5% change) in the past three months and agree to follow reproductive safety measures.Check my eligibility
What is being tested?
The study tests LY3305677 against a placebo over approximately 62 weeks to see if it's effective and safe for managing weight in obese or overweight adults. It follows a master protocol, meaning it's part of larger research efforts.See study design
What are the potential side effects?
Specific side effects are not listed here, but typically trials like this monitor for any negative reactions ranging from mild discomforts such as nausea or headaches to more serious issues related to metabolism or heart function.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 56
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 56 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Absolute Change from Baseline in Liver Fat Content by MRI-PDFF
Absolute Change from Baseline in Liver Fat Content by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)
Change from Baseline in BMI
+9 more

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: LY3305677 Dose 3Experimental Treatment1 Intervention
Participants will receive LY3305677 SC.
Group II: LY3305677 Dose 2Experimental Treatment1 Intervention
Participants will receive LY3305677 SC.
Group III: LY3305677 Dose 1Experimental Treatment1 Intervention
Participants will receive LY3305677 subcutaneously (SC).
Group IV: PlaceboPlacebo Group1 Intervention
Participants will receive LY3305677 matching placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
LY3305677
2017
Completed Phase 1
~180

Find a Location

Who is running the clinical trial?

Eli Lilly and CompanyLead Sponsor
2,620 Previous Clinical Trials
3,216,434 Total Patients Enrolled
55 Trials studying Obesity
51,054 Patients Enrolled for Obesity
Study DirectorEli Lilly and Company
1,348 Previous Clinical Trials
415,580 Total Patients Enrolled
38 Trials studying Obesity
30,773 Patients Enrolled for Obesity

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What risks does the administration of LY3305677 Dose 1 pose to individuals?

"There is evidence of LY3305677 Dose 1's safety in our Phase 2 trial, so it was rated a two. Unfortunately, the data does not yet support its efficacy."

Answered by AI

Could I be considered a suitable candidate to participate in this experiment?

"In order to be part of this clinical trial, patients must have a diagnosis of obesity and fall within the 18-75 year old demographic. Furthermore, 165 individuals are required for the study's completion."

Answered by AI

Are individuals aged 50 and over being sought for this experiment?

"This medical trial looks for participants aged eighteen and above, to no more than seventy-five years old."

Answered by AI

In which locales can this experiment be accessed?

"Patients are being recruited to this clinical trial from 24 different medical sites, spanning Scottsdale, Tucson and Huntington Park alongside 21 other locations. It is recommended that participants select the nearest location in order to reduce travel obligations."

Answered by AI

Are there any vacancies remaining for participants in this experiment?

"As indicated by the clinicaltrials.gov portal, this trial is not presently enrolling patients; however, it was initially posted on November 17th 2023 with its last update occurring nearly two weeks prior on November 6th 2023. Despite no longer searching for participants, there are a plethora of other trials that remain in active recruitment mode currently."

Answered by AI

Who else is applying?

What site did they apply to?
The Institute for Liver Health II dba Arizona Liver Health-Tucson
Peninsula Research Associates
The Institute for Liver Health dba Arizona Clinical Trials
Other
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria

Why did patients apply to this trial?

Need to loose weight. I’m trying lose weight. Lose weight make money. Tried multiple diets and contrave.
PatientReceived 1 prior treatment
I have no other ways to lose weight and get healthy.
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight
2023. "A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06124807.
All > Paid Studies Las Vegas > Honolulu
~96 spots leftby Nov 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top